Target intelligence / Profile preview

Lysosomal activity and autophagy pathways

Molecular classification
Other (cellular degradation system), Enzyme (lysosomal hydrolases), Transporter (lysosomal membrane transporters), Receptor (autophagy receptors, e.g., LAMP2A), Kinase (e.g., mTORC1, regulatory kinase[1])
01

Overview

The autophagy pathway is a conserved cellular process enabling the degradation and recycling of cytoplasmic material within lysosomes, ensuring cellular homeostasis and adaptation to stressors such as starvation[1][2][3]. Lysosomal activity is essential for autophagic flux, which relies on over 60 hydrolases for breakdown of macromolecules. There are several types of autophagy: macroautophagy, chaperone-mediated autophagy, and microautophagy, each differing in how cytoplasmic components are targeted to lysosomes[1][3]. The pathway is tightly regulated by nutrient sensing kinases (notably mTORC1) and is implicated in diverse biological functions and diseases. Specific components of this pathway (rather than the entire system) are therapeutic and research targets, such as mTORC1, LAMP2A, and various autophagy-related proteins[1][2][3]. For structured analyses and data, queries should specify a particular protein, receptor, or enzyme within these pathways (e.g., "LAMP2A," "mTORC1," "ATG5") rather than the holistic system.

Other names
Lysosomal-autophagy systemLysosome-autophagy axisAutophagic lysosome activityLysosomal pathway
02

Mechanism of action

mTOR inhibition: induces autophagy Lysosomal acidification: restores autophagic flux in disease settings Autophagy induction or blockade: impacts cellular survival, protein clearance[1]

03

Biological functions

Cellular degradationOrganelle turnoverProtein recyclingMetabolic regulationResponse to starvationImmune response (removal of intracellular pathogens)Cell survival and cell death[1][2][3]
04

Disease associations

Neurodegenerative disease (e.g., impaired autophagy in Parkinson’s, Alzheimer’s)Cancer (autophagy enables tumor survival, can be pro/anti-tumorigenic)Infection (intracellular pathogen clearance)Metabolic disease (lysosomal storage disorders)
05

Safety considerations

Overstimulation of autophagy can result in excessive cell deathInhibition (e.g., in cancer) could promote accumulation of damaged organelles/proteinsImpaired lysosomal function leads to metabolic/storage disorders[1][3]
06

Interacting drugs

mTOR inhibitors (rapamycin)

2 more in the full profile.

07

Biomarkers

LC3-II (autophagosome marker)LAMP2A (CMA marker)p62/SQSTM1 (selective autophagy)lysosomal enzyme activity[1][2]

Beyond the preview

Go deeper on Lysosomal activity and autophagy pathways.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lysosomal activity and autophagy pathways.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call